focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insur Regulatory News (SBRE)

Share Price Information for Sabre Insur (SBRE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 162.20
Bid: 161.00
Ask: 161.80
Change: 1.20 (0.75%)
Spread: 0.80 (0.497%)
Open: 161.00
High: 162.20
Low: 160.80
Prev. Close: 161.00
SBRE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Oct 2018 07:00

RNS Number : 6525D
Sabre Insurance Group PLC
11 October 2018
 

11 October 2018

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2018.

Summary

· The Group continues its strategy of focusing on underwriting profitability over growth

· Superior underwriting performance, underpinned by strong claims experience in the period under review, supports the Group's continued expectation of delivering a FY 2018 combined ratio better than our mid-70%'s target and slightly higher than the FY 2017 combined ratio, which was 68.5%

· Strong organic capital generation supports the potential for an attractive full-year dividend with a solvency coverage ratio of 195%(1) as at the end of September, above our 140% - 160% target range

· Appropriate pricing actions taken to cover anticipated claims inflation, with GWP for the first nine months of the year remaining broadly flat year on year at £162.6m(1) (2017: £165.0m). The Group maintains its expectations for FY 2018 GWP to be in line with 2017

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of strong competition in the UK motor insurance sector, we have continued to apply our core philosophy of focusing on underwriting profitability, with volume remaining an output rather than target.

As communicated earlier in the year, we have sought to cover anticipated claims inflation and will continue this focus throughout the rest of this year. Whilst premiums for Q3 2018 were slightly below a strong comparative period in Q3 2017, we remain confident that we will end the year with premium in-line with 2017.

Our absolute focus on profitability has yielded a strong underwriting result for the year to date and has allowed us to generate significant excess capital during the period under review. Having paid an interim dividend of 7.2 pence per share, the solvency capital ratio as at 30 September 2018 is at 195%, well above our target operating range of 140%-160%. This provides the Board the option to return surplus capital to shareholders following the full-year results, should the capital position improve further throughout the remainder of 2018. 

(1) Numerical information not subject to audit

 

 

Media enquiries

Tulchan Communications LLP

James Macey White, Roger Tejwani & David Ison

020 7353 4200

sabre@tulchangroup.com

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood

adam.westwood@sabre.co.uk

07776 649 119

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFFUFISFASELS
Date   Source Headline
15th May 20242:24 pmRNSHolding(s) in Company
13th May 202412:23 pmRNSDirector/PDMR Shareholding
23rd Apr 20244:00 pmRNSHolding(s) in Company
22nd Apr 20243:22 pmRNSHolding(s) in Company
19th Apr 20248:51 amRNSChair Appointment
18th Apr 202411:22 amRNSDirector Declaration
11th Apr 202412:41 pmRNSDirector/PDMR Shareholding
11th Apr 202412:07 pmRNSDirector/PDMR Shareholding
9th Apr 20242:44 pmRNSDirector/PDMR Shareholding
5th Apr 20243:48 pmRNSNotice of AGM
21st Mar 202412:30 pmRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSFull-year results 2023
13th Mar 20249:33 amRNSNotice of Results
12th Mar 20242:16 pmRNSDirector/PDMR Shareholding
12th Mar 202412:14 pmRNSDirector Declaration
16th Feb 20241:52 pmRNSHolding(s) in Company
15th Feb 20247:00 amRNSTrading Statement
13th Feb 20242:18 pmRNSDirector/PDMR Shareholding
11th Jan 202411:11 amRNSDirector/PDMR Shareholding
20th Dec 20232:24 pmRNSHolding(s) in Company
12th Dec 202312:03 pmRNSDirector/PDMR Shareholding
28th Nov 20234:27 pmRNSDirectorate Change
27th Nov 20234:42 pmRNSRemuneration Committee Chair Appointment
22nd Nov 20238:51 amRNSNotification of cyber incident
20th Nov 20237:00 amRNSDeath of Chair
13th Nov 202311:44 amRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSTrading Update
11th Oct 202312:52 pmRNSDirector/PDMR Shareholding
25th Sep 20233:39 pmRNSDirector/PDMR Shareholding
21st Sep 202311:48 amRNSDirector/PDMR Shareholding
14th Sep 20232:25 pmRNSHolding(s) in Company
13th Sep 202310:00 amRNSDirector/PDMR Shareholding
13th Sep 20239:33 amRNSDirectorate Change
11th Aug 202310:07 amRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report 2023
25th Jul 20238:53 amRNSDirector Declaration
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
13th Jun 202310:09 amRNSDirector/PDMR Shareholding
2nd Jun 20233:02 pmRNSDirector/PDMR Shareholding
25th May 202311:22 amRNSResult of AGM
25th May 20239:27 amRNSDirector/PDMR Shareholding
25th May 20237:01 amRNSBoard Appointment
25th May 20237:00 amRNSTrading Update
11th May 202311:42 amRNSDirector/PDMR Shareholding
18th Apr 20233:19 pmRNSDirector/PDMR Shareholding
12th Apr 202311:53 amRNSDirector/PDMR Shareholding
6th Apr 202312:28 pmRNSDirector/PDMR Shareholding
31st Mar 20233:43 pmRNSNotice of AGM
31st Mar 20233:37 pmRNSDirector/PDMR Shareholding
14th Mar 20237:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.